Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.

Author information

1
Department of Hematology/Oncology, Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.
2
Department of Hematology/Oncology, Internal Medicine, Samsung Medical Center, Seoul, Korea.
3
Department of Hematology/Oncology, Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
4
Department of Hematology/Oncology, Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
5
Department of Hematology/Oncology, Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
6
Department of Hematology/Oncology, Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
7
Department of Hematology/Oncology, Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
8
Department of Hematology/Oncology, Internal Medicine, Soonchunhyang University Hospital, Seoul, Korea.
9
Department of Hematology/Oncology, Internal Medicine, Wonkwang University Hospital, Iksan, Korea.
10
Department of Hematology/Oncology, Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea.
11
Department of Hematology/Oncology, Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
12
Department of Hematology/Oncology, Internal Medicine, Hallym University Scared Heart Hospital, Anyang, Korea.
13
Department of Hematology/Oncology, Internal Medicine, Dong-A University Hospital, Busan, Korea.
14
Department of Hematology/Oncology, Internal Medicine, Korea Cancer Center Hospital, Seoul, Korea.
15
Department of Hematology/Oncology, Internal Medicine, Asan Medical Center, Seoul, Korea.

Abstract

BACKGROUND:

We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.

METHODS:

We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.

RESULTS:

The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.

CONCLUSION:

Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

KEYWORDS:

Chemotherapy; Epidemiology; Mantle cell lymphoma; Rituximab; Survival; Trend

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Society of Hematology Icon for PubMed Central
    Loading ...
    Support Center